218594-01-5

Basic information

• Product Name: 3-(2-OXO-ETHYL)-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 3-(2-OXO-ETHYL)-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER;(S)-N-Boc-3-morpholinecarbaldehyde;(S)-tert-butyl 3-formylmorpholine-4-carboxylate;(S)-4-Boc-3-morpholinecarbaldehyde;tert-Butyl (3S)-3-formylmorpholine-4-carboxylate;(3S)-4-Boc-3-formyl-morpholine;4-Morpholinecarboxylicacid, 3-formyl-, 1,1-dimethylethyl ester, (3S)-
• CAS NO: 218594-01-5
• Molecular Formula: C₁₀H₁₇NO₄
• Molecular Weight: 229.27
• Mol File: 218594-01-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 330ºC at 760 mmHg
• Flash Point: 153.4ºC
• Appearance: /
• Density: 1.088g/cm3
• Vapor Pressure: 0.000171mmHg at 25°C
• Refractive Index: 1.462
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 3-(2-OXO-ETHYL)-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-OXO-ETHYL)-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER(218594-01-5)
• EPA Substance Registry System: 3-(2-OXO-ETHYL)-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER(218594-01-5)

Safety Data

• Hazardous Substances Data: 218594-01-5(Hazardous Substances Data)

Usage

Description

3-(2-OXO-ETHYL)-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER is an organic compound that serves as an intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its unique chemical structure, which includes a morpholine ring and a tert-butyl ester group, making it a versatile building block in the development of new drugs.

Uses

Used in Pharmaceutical Industry:
3-(2-OXO-ETHYL)-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a key intermediate in the synthesis of dihydrobenzodioxine derivatives and analogs. These compounds act as RAS-effector protein interaction inhibitors, which are crucial in the development of targeted therapies for various cancers and other diseases.
In the preparation of these RAS-effector protein interaction inhibitors, 3-(2-OXO-ETHYL)-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER plays a vital role in the formation of the final drug molecule. Its unique chemical properties allow for the creation of potent and selective inhibitors that can effectively disrupt the interaction between RAS proteins and their downstream effectors, thereby inhibiting the signaling pathways involved in the development and progression of cancer.
Furthermore, the use of 3-(2-OXO-ETHYL)-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER in the pharmaceutical industry highlights its potential in the development of novel therapeutic agents. Its versatility as a synthetic intermediate opens up possibilities for the creation of a wide range of drug candidates, targeting various diseases beyond cancer, such as autoimmune disorders, neurological conditions, and inflammatory diseases.

InChI:InChI=1/C11H19NO4/c1-11(2,3)16-10(14)12-5-7-15-8-9(12)4-6-13/h6,9H,4-5,7-8H2,1-3H3

Upstream product

• 783350-37-8 (S)-4-[(tert-butoxy)carbonyl]morpholine-3-carboxylic acid 
• 215917-99-0 (R)-3-(hydroxymethyl)morpholine-4-carboxylic acid tert-butyl ester 

Relevant articles and documents

DIHYDROPYRIMIDINYLTHIAZOLE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The present invention provides novel compounds having the general formula: wherein R1, R2, X, Y and A are as described herein, compositions including the compounds and methods of using the compounds.

Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors

Described herein are the discovery and structure-activity relationship (SAR) studies of the third-generation 4-H heteroaryldihydropyrimidines (4-H HAPs) featuring the introduction of a C6 carboxyl group as novel HBV capsid inhibitors. This new series of 4-H HAPs showed improved anti-HBV activity and better drug-like properties compared to the first- and second-generation 4-H HAPs. X-ray crystallographic study of analogue 12 (HAP_R01) with Cp149 Y132A mutant hexamer clearly elucidated the role of C6 carboxyl group played for the increased binding affinity, which formed strong hydrogen bonding interactions with capsid protein and coordinated waters. The representative analogue 10 (HAP_R10) was extensively characterized in vitro (ADMET) and in vivo (mouse PK and PD) and subsequently selected for further development as oral anti-HBV infection agent.

PROCESSES FOR PREPARING DIHYDROPYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF

The present invention refers to processes for preparing a dihydropyrimidine compound having Formula (I), or a tautomer thereof having Formula (la), as well as a intermediate thereof. The process of the invention has simple operation, high optical purity of product, high yield and convenient work-up, which is suitable for industrial production.